Crawford four-month appraisal
This article was originally published in The Tan Sheet
Executive SummaryActing FDA Commissioner Lester Crawford, PhD, "is doing an awesome job," HHS Secretary Tommy Thompson tells AdvaMed board members June 20 in Washington, D.C. "He is out there to make changes. He is already making more changes in the short couple [of] months he's been here...realigning, reorganizing, putting in the risk assessment system....Whether or not he's going to get to be the commissioner I can't tell you. That's a decision for the President. But I can assure you, until the final commissioner is appointed by the President, this man is in charge, this man is going to continue to make changes"...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.